IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: bob zagorin who wrote (1715)	5/29/2000 9:51:00 PM
From: Maurice Winn	1 Recommendation of 1762

<They also expect Zevalin BLA in Q4. They say its superior to Coulter's Bexxar because since its linked to radioscope, doesn't have penetrating emissions and can be given as outpatient. > While that's nice, the issue of most importance is how many people are still alive 2, 5 and 10 years after treatment. I'd prefer a month of inpatient time with a 1% improved survival prospect than outpatient treatment with reduced survival prospects. Which product gives improved survival prospects and can those differences be narrowed down to individuals rather than overall statistics? That's the main question. Maurice

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next